Lv5
860 积分 2022-07-27 加入
Markers of refractory primary immune thrombocytopenia
2个月前
已完结
Multicentre, randomised phaseIIIstudy of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia
2个月前
已完结
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink
2个月前
已完结
Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study
3个月前
已完结
The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments
3个月前
已完结
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
3个月前
已完结
Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia
3个月前
已完结
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
3个月前
已完结
Assessing TP53 status in human tumours to evaluate clinical outcome
6个月前
已完结
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
6个月前
已完结
皖公网安备34019202002308
